First patient dosed in long-term Alzheimer’s trial October 6, 2020 Auto Bot Clinical Development 0 Neurotrope has kicked off its ongoing Phase II study of Bryostatin-1 for treatment of Alzheimerâs disease, with the help of a $2.7m NIH grant.
